CoChat

Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters—a randomized, double‐blind, placebo‐controlled trial

Open access
Detyniecki, Kamil, Van Ess, Peter J., Sequeira, David J., Wheless, James W., Meng, Tze‐Chiang, Pullman, William E. · 2019 · Epilepsia
Cited by 105

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Objective: To evaluate the safety and efficacy of a novel formulation of midazolam administered as a single‐dose nasal spray ( MDZ – NS ) in the outpatient treatment of patients experiencing seizure clusters ( SC s). Methods: This was a phase III , randomized, double‐blind, placebo‐controlled trial (ClinicalTrials.gov NCT 01390220) with patients age ≥12 years on a stable regimen of antiepileptic drugs. Following an in‐clinic test dose phase ( TDP ), patients entered an outpatient comparative phase ( CP ) and were randomized (2:1) to receive double‐blind MDZ – NS 5 mg or placebo nasal spray, administered by caregivers when they experienced an SC . The primary efficacy end point was treatment success (seizure termination within 10 minutes and no recurrence 10 minutes to 6 hours after trial drug administration). Secondary efficacy end points were proportion of patients with seizure recurrence 10 minutes to 4 hours, and time‐to‐next seizure >10 minutes after double‐blind drug administration. Safety was monitored throughout. Results: Of 292 patients administered a test dose, 262 patients were randomized, and 201 received double‐blind treatment for an SC (n = 134 MDZ – NS , n = 67 placebo, modified intent‐to‐treat population). A significantly greater proportion of MDZ – NS ‐ than placebo‐treated patients achieved treatment success (53.7% vs 34.4%; P = 0.0109). Significantly, fewer MDZ – NS ‐ than placebo‐treated patients experienced seizure recurrence (38.1% vs 59.7%; P = 0.0043). Time‐to‐next seizure analysis showed early separation (within 30 minutes) between MDZ – NS and placebo that was maintained throughout the 24‐hour observation period (21% difference at 24 hours; P = 0.0124). Sixteen patients (5.5%) discontinued because of a treatment‐emergent adverse event ( TEAE ) during the TDP and none during the CP . During the CP , 27.6% and 22.4% of patients in the MDZ – NS and placebo groups, respectively, experienced ≥1 TEAE . Significance: MDZ – NS was superior to placebo in providing rapid, sustained seizure control when administered to patients experiencing an SC in the outpatient setting and was associated with a favorable safety profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/epi.15159

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 105

Metadata

Authors
Detyniecki, K., Van Ess, P. J., Sequeira, D. J., Wheless, J. W., Meng, T., & Pullman, W. E.
Venue
Epilepsia
Publisher
Wiley
Published
2019-05-29
Volume
60
Issue
9
Pages
1797-1808
ISSN
  • 0013-9580 (ISSN-L)
  • 1528-1167
OpenAlex
W2947233910
Cited by
105
References
5
FWCI
9.14
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters—a randomized, double‐blind, placebo‐controlled trial. https://app.cochat.ai/papers/10.1111/epi.15159
The paper
Detyniecki, K., Van Ess, P. J., Sequeira, D. J., Wheless, J. W., Meng, T., & Pullman, W. E. (2019). Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters—a randomized, double‐blind, placebo‐controlled trial. Epilepsia. https://doi.org/10.1111/epi.15159

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.